Drug Trial Radar · NCT03746587
Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3
Last checked: Nov 19, 2026Latest source record: Jan 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
39
Actual
Start
Jun 6, 2018
Primary completion
Apr 1, 2020
Study completion Oct 15, 2021
Sponsor
- Lead sponsor
- ZevraDenmarkIndustry
- Sponsor type
- Industry
- First posted
- Nov 19, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 4 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multicenter, doubleblinded, randomized placebo-controlled study of arimoclomol in patients with Gaucher Disease Type 1 or 3
Conditions
- Gaucher Disease, Type 1
- Gaucher Disease, Type 3
Interventions
ArimoclomolDrug
Arimoclomol in 3 different dosages
Placebo oral capsuleDrug
Matching placebo capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary EndpointTime frame: 6 months
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Maulana Azad Medical College
New Delhi, India
All India Institute of Medical Sciences
New Delhi, India
King Edward Memorial Hospital
Mumbai, Maharashtra, India
Jaslok Hospital and Reseach Centre
Mumbai, Maharashtra, India
KEM HOSPITAL Research Centre
Pune, Maharashtra, India
Sir Ganga Ram Hospital
New Delhi, National Capital Territory of Delhi, India
Christian Medical College and Hospital.
Vellore, Tamil Nadu, India
Institute of Child Health
Kolkata, West Bengal, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.